European Journal of Clinical Pharmacology

, Volume 25, Issue 4, pp 463–466 | Cite as

Pharmacokinetic aspects of guanfacine withdrawal syndrome in a hypertensive patient with chronic renal failure

  • J. R. Kiechel
  • D. Lavene
  • M. Guerret
  • E. Comoy
  • M. Godin
  • J. P. Fillastre
Originals

Summary

The unusual observation of a withdrawal syndrome due to guanfacine in a hypertensive patient with chronic renal failure led to a study of the kinetics of the drug in this patient. The principal pharmacokinetic parameters of guanfacine were greatly altered, with extended biotransformation and a decrease in the half-life compared to the values observed in other cases of severe renal insufficiency. Associated treatment with phenobarbital had had a considerable effect, as shown by the results of a further kinetic study 2 months after withdrawal of the phenobarbital. The findings then were in good agreement with reference values which strongly suggests a consequence of the enzyme inducing effect of phenobarbital. Advice about the dosage regimen in such cases is given.

Key words

guanfacine hypertension phenobarbital withdrawal syndrome enzyme induction pharmacokinetics renal insufficiency 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Saameli K, Scholtysik G, Waite R (1975) Pharmacology of BS 100–141, a centrally acting antihypertensive drug. Clin Exp Pharmacol Physiol 2 (Suppl 2): 207–212Google Scholar
  2. 2.
    Jäättelä A (1976) Clinical efficacy of BS 100–141 in essential hypertension. A single-blind pilot study. Eur J Clin Pharmacol 10: 69–72Google Scholar
  3. 3.
    Turner AS (1974) A study of BS 100–141 in the treatment of arterial hypertension. In: Romano FJ, Perosio AM, Malamud B et al (eds) 7th World Congress of Cardiology, Buenos Aires, Sept. 1–7, Abstract n° 336Google Scholar
  4. 4.
    Kiechel JR (1980) Pharmacokinetics and metabolism of guanfacine in man: a review. Br J Clin Pharmacol 10: 25S-32SGoogle Scholar
  5. 5.
    Kiechel JR, Lavène D, Guerret M, Coustenoble J, Petrover M, Godin M, Fillastre JP (1980) Etude pharmacocinétique de la guanfacine chez l'insuffisant rénal et l'hémodialysé. Néphrologie 1: 73–81Google Scholar
  6. 6.
    Jerie P (1980) Clinical experience with guanfacine in long-term treatment of hypertension. Part II: adverse reactions to guanfacine. Br J Clin Pharmacol 10: 157S-164SGoogle Scholar
  7. 7.
    Guerret M, Lavèvne D, Longchampt J, Kiger JL (1979) Determination of guanfacine in biological fluids by electron-capture GLC. J Pharm Sci 68: 219–221Google Scholar
  8. 8.
    Guerret M, Julien-Larose C, Kiechel JR, Lavène D (1982) Determination of 3-hydroxy-guanfacine in biological fluids by electron-capture gas-liquid chromatography. J Chromatogr 233: 181–192Google Scholar

Copyright information

© Springer-Verlag 1983

Authors and Affiliations

  • J. R. Kiechel
    • 1
    • 2
  • D. Lavene
    • 1
    • 2
  • M. Guerret
    • 1
    • 2
  • E. Comoy
    • 1
    • 2
  • M. Godin
    • 1
    • 2
  • J. P. Fillastre
    • 1
    • 2
  1. 1.Laboratoire de Recherche SandozParisFrance
  2. 2.Service de Biochimie, Institut Gustave RoussyVillejuif and Service de Nephrologie C.H.R.RouenFrance

Personalised recommendations